HC Wainwright reiterated their buy rating on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI) in a research note issued to investors on Tuesday morning. They currently have a $11.00 price objective on the biotechnology company’s stock.
A number of other equities research analysts also recently issued reports on BCLI. Maxim Group set a $9.00 price objective on shares of Brainstorm Cell Therapeutics and gave the company a buy rating in a research report on Monday, May 14th. ValuEngine raised shares of Brainstorm Cell Therapeutics from a sell rating to a hold rating in a research report on Tuesday, March 13th.
Shares of BCLI stock opened at $3.90 on Tuesday. Brainstorm Cell Therapeutics has a 1 year low of $2.88 and a 1 year high of $5.35.
Brainstorm Cell Therapeutics (NASDAQ:BCLI) last issued its quarterly earnings data on Monday, May 14th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.02. sell-side analysts forecast that Brainstorm Cell Therapeutics will post -0.57 earnings per share for the current fiscal year.
Several hedge funds have recently modified their holdings of the company. Renaissance Technologies LLC grew its position in shares of Brainstorm Cell Therapeutics by 396.9% during the 4th quarter. Renaissance Technologies LLC now owns 114,550 shares of the biotechnology company’s stock valued at $449,000 after acquiring an additional 91,495 shares during the period. Deutsche Bank AG grew its position in shares of Brainstorm Cell Therapeutics by 330.0% during the 4th quarter. Deutsche Bank AG now owns 98,590 shares of the biotechnology company’s stock valued at $386,000 after acquiring an additional 75,664 shares during the period. Finally, Clearline Capital LP bought a new stake in shares of Brainstorm Cell Therapeutics during the 4th quarter valued at $208,000. 8.29% of the stock is owned by hedge funds and other institutional investors.
Brainstorm Cell Therapeutics Company Profile
Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of central nervous system (CNS) adult stem cell therapies designed to address the unmet medical needs of patients with debilitating neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes a patient's own cells, which are engineered outside the body, to produce and secrete factors known to promote neuronal survival.
Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.